Great West Life Assurance Co. Can Purchases 4,145 Shares of Amicus Therapeutics, Inc. (FOLD)

Great West Life Assurance Co. Can increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 40.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,445 shares of the biopharmaceutical company’s stock after buying an additional 4,145 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Amicus Therapeutics were worth $212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in FOLD. JGP Global Gestao de Recursos Ltda. bought a new stake in Amicus Therapeutics in the third quarter valued at approximately $570,000. TD Asset Management Inc. boosted its holdings in Amicus Therapeutics by 86.1% in the third quarter. TD Asset Management Inc. now owns 225,454 shares of the biopharmaceutical company’s stock valued at $3,400,000 after acquiring an additional 104,294 shares during the last quarter. American International Group Inc. boosted its holdings in Amicus Therapeutics by 23.1% in the third quarter. American International Group Inc. now owns 109,628 shares of the biopharmaceutical company’s stock valued at $1,653,000 after acquiring an additional 20,597 shares during the last quarter. Sphera Funds Management LTD. boosted its holdings in Amicus Therapeutics by 5.0% in the third quarter. Sphera Funds Management LTD. now owns 420,000 shares of the biopharmaceutical company’s stock valued at $6,334,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Columbus Circle Investors boosted its holdings in Amicus Therapeutics by 118.2% in the third quarter. Columbus Circle Investors now owns 199,874 shares of the biopharmaceutical company’s stock valued at $3,014,000 after acquiring an additional 108,252 shares during the last quarter.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $14.38 on Wednesday. Amicus Therapeutics, Inc. has a 12 month low of $4.77 and a 12 month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. The firm has a market capitalization of $2,354.37, a price-to-earnings ratio of -7.86 and a beta of 1.76.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The company had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm’s revenue for the quarter was up 419.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.33) EPS. research analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

FOLD has been the topic of several analyst reports. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Chardan Capital reiterated a “buy” rating and issued a $16.50 target price (down from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Tuesday, October 10th. Cowen reiterated an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a report on Thursday, September 14th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.81.

In other Amicus Therapeutics news, CEO John F. Crowley sold 449,295 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. Following the transaction, the chief executive officer now directly owns 380,723 shares of the company’s stock, valued at approximately $5,455,760.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Crowley sold 71,735 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $14.75, for a total value of $1,058,091.25. Following the completion of the transaction, the chief executive officer now directly owns 380,723 shares in the company, valued at $5,615,664.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 758,224 shares of company stock worth $10,785,546. 3.40% of the stock is currently owned by insiders.

WARNING: “Great West Life Assurance Co. Can Purchases 4,145 Shares of Amicus Therapeutics, Inc. (FOLD)” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/27/great-west-life-assurance-co-can-purchases-4145-shares-of-amicus-therapeutics-inc-fold.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

What are top analysts saying about Amicus Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amicus Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit